Search Results for: 19

— Conference Call Scheduled for Thursday, March 10, 2016 at 4:30 p.m. EST — ROCKVILLE, Md., March 3, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, intends to release its financial results for the year ended December 31, 2015 on Thursday, March […]

— New Allowances Bolster Strong SYN-004 Patent Estate — ROCKVILLE, Md., March 1, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that the U.S. Patent and Trademark Office (USPTO) issued Notices of Allowance for three patent applications which cover composition

— Company Continues to Strengthen Patent Estate Related to SYN-010 — ROCKVILLE, Md., Feb. 17, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent application

ROCKVILLE, Md., Feb. 16, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that Jeffrey Riley, President & Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat with the Company’s covering analyst, Adnan Butt, at the 2016 RBC

ROCKVILLE, Md., Feb. 3, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 8, 2016, at 8:30 a.m. (ET) at the Waldorf

— Data Analysis Did Not Demonstrate Statistically Significant Differences Between Treatment and Placebo Groups — ROCKVILLE, Md., Feb. 2, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, today reported independent third party analysis of the investigator-sponsored Phase 2 clinical trial that evaluated

— SYN-010 Demonstrated Ability to Reduce Methane Production, Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores in IBS-C Patients — — Conference Call Wednesday, Jan. 20, 2016, at 8:30 a.m. (ET); Mark Pimentel, MD, FRCP(C) Featured Guest Speaker — ROCKVILLE, Md., Jan. 19, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT:

ROCKVILLE, Md., Jan. 6, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that Jeff Riley, CEO, is scheduled to present at the Biotech Showcase™ 2016 Conference next week in San Francisco, as follows: Date: Monday, January 11, 2016Time: 11:00 a.m.

— Second Phase 2 Eight Week Extension Study Results Expected in 1Q2016 — — Planning Underway for Initiation of SYN-010 Phase 3 Clinical Trial During 2016 — — SYN to Host Microbiome Clinical Program Seminar in NYC on Thursday, December 10, 2015 — ROCKVILLE, Md., Dec. 8, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN),

— Event to Feature Company’s Two Phase 2 Clinical Programs for Treatment of Irritable Bowel Syndrome with Constipation and Prevention of C. difficile Infection — — Live Webcast Scheduled at 9:00 a.m. EST on Thursday, December 10, 2015 — ROCKVILLE, Md., Dec. 7, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company